Iterative Health Expands into Cardiology with US Heart & Vascular Partnership
Event summary
- Iterative Health partners with US Heart & Vascular to expand into cardiovascular research, adding over 100 new sites across three continents.
- USHV's clinical research sites will integrate into Iterative Health’s operational backbone for end-to-end trial support.
- The deal marks Iterative Health’s first foray into cardiology, complementing its existing focus on GI, hepatology, and obesity.
- Thomas Waggoner, MD, Structural Cardiologist at Pima Heart & Vascular, will champion the initiative.
The big picture
This partnership reflects a broader industry shift toward decentralizing clinical trials, bringing them closer to patients in community settings. By expanding into cardiology, Iterative Health strengthens its position as a multispecialty research partner, potentially attracting more biopharma sponsors seeking scalable trial solutions.
What we're watching
- Execution Risk
- Whether Iterative Health can seamlessly integrate USHV’s sites into its existing operational model.
- Market Penetration
- The pace at which the partnership accelerates cardiovascular trial enrollment and therapy access in community settings.
- Competitive Dynamics
- How this move positions Iterative Health against specialized cardiology research networks.